Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.55 |
| ▸ | DHFR | P00374 | 9/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | DCPS | Q96C86 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335843 | 0.82 | HSP90AB1 (0.57) | HSP90AB1PIK3CGMAP4K4DCPS | |
| SCHEMBL28899984 | 0.71 | HSP90AB1 (0.54) | HSP90AB1PIK3CGMAP4K4 | |
| SCHEMBL25367735 | 0.71 | F2R (0.56) | DHFRSLC2A1 | |
| SCHEMBL30588930 | 0.71 | F2R (0.56) | DHFRSLC2A1 | |
| SCHEMBL8388586 | 0.71 | CDK9 (0.45) | DHFRPIK3CGSLC2A1DCPS | |
| SCHEMBL6652422 | 0.71 | TYMS (1.00) | TYMS | |
| SCHEMBL1611666 | 0.71 | SLC2A1 (0.51) | DHFRSLC2A1DCPS | |
| SCHEMBL9054022 | 0.69 | HSP90AA1 (0.53) | DHFRHSP90AB1SLC2A1DCPS | |
| SCHEMBL4351919 | 0.69 | DHFR (0.58) | DHFRHSP90AB1MAP4K4 | |
| SCHEMBL8389944 | 0.69 | SLC2A1 (0.44) | DHFRSLC2A1MAP4K4DCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122580-A1 | METHOD OF TREATING CHRONIC PAIN USING INHIBITOR OF NEUROPILIN-1 (NRP1) AND G ALPHA INTERACTING PROTEIN (GAIP) INTERACTING PROTEIN C-TERMINUS 1 (GIPC1) | NEW YORK UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-2914621-B1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUND MEDICINE INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | NTRK1, NTRK3, NTRK2 | TYMS 1945/4885DHFR 3460/4885HSP90AB1 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.